Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
13.
Dermatol Online J ; 19(10): 20022, 2013 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-24139365

RESUMEN

Scedosporium apiospermum is a filamentous fungus that can cause cutaneous or extracutaneous disease. A large number of cases have been published over the last decades, mainly in patients immunocompromised as a result of their disease or treatment. These kinds of infections can progress rapidly and become disseminated, leading to very serious or even fatal complications. We report two new cases of skin infection by Scedosporium apiospermum from our hospital.


Asunto(s)
Antifúngicos/uso terapéutico , Dermatomicosis/inmunología , Huésped Inmunocomprometido , Naftalenos/administración & dosificación , Pirimidinas/administración & dosificación , Scedosporium/aislamiento & purificación , Triazoles/administración & dosificación , Absceso/tratamiento farmacológico , Absceso/cirugía , Anciano , Dermatomicosis/diagnóstico , Dermatomicosis/tratamiento farmacológico , Humanos , Masculino , Scedosporium/efectos de los fármacos , Terbinafina , Voriconazol
15.
Diagn Microbiol Infect Dis ; 30(2): 103-7, 1998 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9554177

RESUMEN

The evolution (from 1990 to 1996) of fluoroquinolone consumption and resistance and the current patterns of fluoroquinolone usage were examined in a 250-bed community hospital in Spain. Fluoroquinolone consumption increased from 1392 g in 1990 to 3203 g in 1996 (p < 0.05). A significant increase in ciprofloxacin resistance was observed in Escherichia coli isolated from urine samples (from 3 to 20%, p < 0.00001), but not in those E. coli isolated from blood or other sample cultures. In 69 randomly selected clinical charts, fluoroquinolone was used as prophylaxis, empirical therapy, and specific directed therapy in 20%, 65%, and 15%, respectively. Evaluation of quinolone indication was: first choice agents (29%), alternative agents (49%), experimental agents (4.3%) and, agents with no role (1.4%). Our study shows that the increase in the use of fluoroquinolones is associated with the emergence of ciprofloxacin-resistant E. coli from urinary tract sources. Based on their indications, current quinolone usage can be greatly reduced.


Asunto(s)
Antibacterianos/uso terapéutico , Ciprofloxacina/uso terapéutico , Escherichia coli/aislamiento & purificación , Anciano , Contraindicaciones , Farmacorresistencia Microbiana , Utilización de Medicamentos , Humanos , Modelos Lineales , Norfloxacino/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA